Answer
Ceritinib weakly inhibits CYP2C9 and can increase warfarin exposure; co-administration should be avoided, but if unavoidable, warfarin dose reduction and more frequent INR monitoring may be considered.
Sources for this answer
- Zykadia 150mg Film-coated TabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked